NCT02538198: Phase 2 - Lenalidomide Maintenance in Plasma Cell Myeloma
Updated: Apr 25, 2022
NCT02538198: Phase 2 - Lenalidomide Maintenance in Plasma Cell Myeloma
This is a Phase 2 study to assess the good and bad effects of maintenance therapy on patients who have been treated for myeloma and no longer show signs of this type of cancer.
Sponsor:
Memorial Sloan Kettering Cancer Center
Official Title: Lenalidomide Maintenance in Plasma Cell Myeloma
ClinicalTrials.gov Identifier: NCT02538198
Official Title: Lenalidomide Maintenance in Plasma Cell Myeloma
Click here to see details on ClinicalTrials.gov
Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial
Interpretation: Serial measurements of MRD allow for dynamic assessment of risk for disease progression. Early intervention should be investigated for patients with loss of MRD negativity. Sustained MRD positivity is not categorically an unfavourable outcome and might portend prolonged stability of low-level disease.
Lancet Haematol; 2021